Cameron D Thomas, Francesco Franchi, Joseph S Rossi, Ellen C Keeley, R David Anderson, Amber L Beitelshees, Julio D Duarte, Luis Ortega-Paz, Yan Gong, Richard A Kerensky, Natasha Kulick, Caitrin W McDonough, Anh B Nguyen, Yehua Wang, Marshall Winget, William E Yang, Julie A Johnson, Almut G Winterstein, George A Stouffer, Dominick J Angiolillo, Craig R Lee, Larisa H Cavallari
BACKGROUND: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear. OBJECTIVES: The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y12 inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI)...
April 16, 2024: Journal of the American College of Cardiology